Sign in Register

Indication

Immunosuppression maintenance therapy for lung transplantation

Immunosuppression maintenance therapy for lung transplantation refers to the lifelong pharmacologic management of individuals who have undergone single, bilateral, or heart-lung transplantation. Read more about Immunosuppression maintenance therapy for lung transplantation

31 drugs 29 manufacturers

Advertisement

Drugs that treat it

Common Immunosuppression maintenance therapy for lung transplantation therapies.

Showing 19–27 of 31 drugs

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
PROFICIENT RX L

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
BRYANT RANCH PR

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
ASCEND LABORATO

TACROLIMUS

MACROLIDE IMMUNOSUPPRESSANTS - TOPICAL·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
GLENMARK PHARMA

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
BIOCON PHARMA I

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
CIVICA, INC.

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
QUALLENT PHARMA

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
AHP

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
CADISTA PHARMAC
Filter & compare in the drug finder →Opens the drug finder with Immunosuppression maintenance therapy for lung transplantation preselected.

News & literature

Coming soon

Related codes

Coming soon

Related conditions & guidelines

Coming soon

About Immunosuppression maintenance therapy for lung transplantation.

Immunosuppression maintenance therapy for lung transplantation refers to the lifelong pharmacologic management of individuals who have undergone single, bilateral, or heart-lung transplantation.

This post-transplant clinical state is characterized by constant vulnerability of the respiratory allograft to host immune recognition, driven by direct exposure of donor lung epithelial and vascular tissue to circulating host leukocytes and inhaled environmental antigens.

Without sustained immune modulation, recipient T-cell and antibody-mediated responses incite vascular and airway inflammation, culminating in acute cellular rejection, antibody-mediated rejection, or chronic lung allograft dysfunction.

Standard maintenance protocols continuously suppress lymphocyte activation and proliferation to preserve long-term graft survival and pulmonary gas exchange while balancing the competing risks of opportunistic infections and systemic toxicities.

Personalize your experience

Follow Immunosuppression maintenance therapy for lung transplantation and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it